Domaine Worldwide and Shopify Launch Enterprise Platform Migration Initiative Across Europe
29.10.2025 11:00:00 EET | Business Wire | Press release
Domaine Worldwide, the leading global Shopify design and development partner, announced the launch of its European Platform Migrations partnership with Shopify today. The initiative positions Domaine as the go-to commerce partner for enterprise-level brands across the UK, DACH, and BENELUX regions looking to migrate to Shopify’s scalable, commerce-ready infrastructure.
As enterprise organizations across Europe face the challenge of modernizing legacy systems, this campaign highlights the combined power of Domaine’s migration expertise and Shopify’s enterprise-grade flexibility—offering brands a seamless path to improved performance, agility, and long-term growth.
“For enterprise retailers, platform migration is no longer just a technical decision—it’s a strategic one. For some, it's become a strategic imperative,” said Marko Bon, Co-founder and President of Domaine. “We’ve seen first-hand how a migration to Shopify is a foundational step in digital business transformation, unlocking streamlined operations, efficiencies across the entire business, and ultimately, measurable ROI. Domaine was purpose-built to guide that transition end-to-end, with teams across Europe who live and breathe Shopify.”
Proven Success with Leading Global Brands
Domaine and Shopify’s partnership is backed by a track record of measurable results from luxury and beauty leaders, including:
- Creed — Achieved a 22.1% increase in Average Order Value and 19% growth in returning customers in the UK.
- Laura Mercier — Drove a 38% Increase in Average Order Value and a 22% Increase in Revenue following migration.
These case studies and others from leading brands like Timex, Milk Makeup, Oscar De La Renta, Mejuri, Keen, Arhaus, Glossier, and Karl Lagerfeld highlight the potential for established brands to achieve transformative gains through a migration to Shopify’s robust ecosystem, supported by Domaine’s in-depth platform knowledge and regional presence.
Solving a Critical Gap for Enterprise Retailers
Across Europe, enterprise brands have had limited options for large-scale platform migrations to Shopify, forced to rely on small generalists, large Salesforce agencies with small Shopify practices, or costly global consultancies. Domaine’s Shopify-only specialization changes that equation. By focusing exclusively on Shopify, the commerce partner offers the largest global team of Shopify SMEs outside of Shopify itself, with specific experience in managing the most complex enterprise migrations—and without the overhead or limitations of legacy providers.
The campaign aims to educate senior decision-makers on the strategic and operational advantages of Shopify for enterprise-scale commerce while showcasing how Domaine simplifies the replatforming process through dedicated migration teams, data-driven methodologies, and regionally aligned support.
“Our message to enterprise brands is simple,” Bon added. “If your current platform is holding you back, Shopify is a proven, future-ready solution, and Domaine is the partner to make that move successful.”
About Domaine Worldwide
Today, Domaine counts over 300 Shopify experts worldwide, including a dedicated European team based across The UK, The Netherlands, Switzerland, Ukraine and Germany. Following its 2025 acquisition of Code—one of Europe’s most respected Shopify Plus agencies and a Platinum Partner in its own right—Domaine has expanded its European footprint while strengthening its local expertise.
That combination of regional understanding and global capability makes Domaine uniquely equipped to support complex migrations and digital growth projects alike—from multinational operations to highly localised customer experiences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251029134084/en/
Contacts
Media Contact
Freyja Wedderkop
freyja.wedderkop@meetdomaine.com
+1 (929) 930-5341
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom